GlassScriptPhysician profile
Vijay N Roy
NPI 1982688925
$14,732.54
in general payments reported to CMS, 2019-2025
61 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,268 · 2020: $580 · 2021: $1,511 · 2022: $796 · 2023: $2,203 · 2024: $3,438 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,204 · Education: $1,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,204.38 |
| Education | $1,373.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,766.90 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| E.R. Squibb & Sons, L.L.C. | $2,052.43 | 2019-2025 | Opdivo, Camzyos, Reblozyl |
| Incyte Corporation | $1,101.92 | 2019-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $1,007.34 | 2019-2025 | Lynparza, Calquence, Enhertu |
| Celgene Corporation | $729.91 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $577.65 | 2019-2024 | Padcev, Xtandi |
| Seagen INC. | $569.17 | 2019-2025 | Padcev, Adcetris |
| Pfizer INC. | $519.25 | 2019-2025 | |
| Genzyme Corporation | $436.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $406.18 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $325.61 | 2019-2025 | Keytruda, Reblozyl, Welireg |
| Amgen INC. | $321.84 | 2019-2023 | Kyprolis, Lumakras, Nplate |
| Coherus Oncology, INC. | $265.00 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $257.53 | 2019-2024 | |
| Beigene USA, INC. | $255.89 | 2023-2025 | Brukinsa |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.